According to a recent LinkedIn post from Glooko, the company is drawing attention to upcoming changes by the Centers for Medicare & Medicaid Services that make inpatient glycemic safety a required performance measure rather than just a clinical priority. The post promotes a March 17 webinar, organized with Becker’s Healthcare, focused on strategies to standardize insulin management and align frontline execution with new CMS expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Glooko is positioning its solutions and expertise around hospital glycemic management as regulatory scrutiny intensifies, which could increase demand for tools that help health systems demonstrate consistent, measurable outcomes. For investors, this emphasis on compliance-driven use cases may reinforce Glooko’s relevance in the hospital segment and potentially support adoption and stickiness of its offerings as providers respond to CMS performance requirements.